Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study

Overview

Journal Adv Ther

Date 2023 Oct 6

PMID 37801232

Authors

Piergiacomo Calzavara-Pinton

Jarmila celakovska

Hilde Lapeere

Gregor Holzer

Mona Al-Ahmad

Chia-Yu Chu

Silvia M Ferrucci

Yoko Kataoka

Mariateresa Rossi

Daria S Fomina

Wen-Hung Chung

Thrasyvoulos Tzellos

Anne-Claire Fougerousse

Jiangming Wu

Marius Ardeleanu

Zafer E Ozturk

Affiliations

Soon will be listed here.

Abstract

Introduction: Insights into real-world treatment of atopic dermatitis (AD) are relevant to clinical decision making. The aim of this analysis was to characterize patients who receive dupilumab for AD in a real-world setting.

Methods: The GLOBOSTAD registry is an ongoing, longitudinal, prospective, observational study of patients with AD who receive dupilumab according to country-specific prescribing information. We report baseline characteristics, comorbidities and treatment patterns for patients enrolled from July 11, 2019 to March 31, 2022. Analyses are descriptive; no formal statistical comparisons were performed.

Results: Nine hundred fifty-two adults and adolescents were enrolled in GLOBOSTAD. Patients had a high disease burden before starting dupilumab: (mean [standard deviation]) percent body surface area affected (44.8 [24.42]), Eczema Area and Severity Index total score (24.8 [12.95]), SCORing Atopic Dermatitis total score (60.5 [16.34]), Patient-Oriented Eczema Measure total score (19.7 [6.37]) and Dermatology Life Quality Index total score (13.7 [7.02]). Overall, 741 (77.8%) patients reported ≥ 1 type 2 inflammatory comorbidities, most frequently allergic rhinitis (492 [51.7%]), asthma (323 [33.9%]), food allergy (294 [30.9%]) or another allergy (274 [28.8%]). In the previous 12 months, 310 (32.6%) patients had received systemic non-steroidal immunosuppressants and 169 (17.8%) systemic corticosteroids; 449 (47.2%) had received topical corticosteroids, most commonly potent topical corticosteroids; 141 (14.8%) had received topical calcineurin inhibitors and 32 (3.4%) ultraviolet therapy. Most (713 [74.9%]) patients started dupilumab because of prior treatment failure.

Conclusion: Patients enrolled in GLOBOSTAD demonstrated considerable multidimensional burden of disease across AD signs, symptoms and quality of life despite previous use of systemic and non-systemic AD treatments.

Clinical Trial Registration: ClinicalTrials.gov identifier NCT03992417. Video Abstract.

Citing Articles

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.

Calzavara-Pinton P, Chu C, Lapeere H, Rossi M, Ferrucci S, Chung W Adv Ther. 2024; 42(2):720-733.

PMID: 39621227 PMC: 11787152. DOI: 10.1007/s12325-024-03049-8.

Illuminating characteristic patterns of inflammatory dermatoses: A comprehensive dual-imaging approach using Optical coherence tomography and Line-field confocal optical coherence tomography.

Deussing M, Ruini C, Nutz M, Kerl-French K, Hartmann D, French L Skin Res Technol. 2024; 30(7):e13833.

PMID: 38961692 PMC: 11222661. DOI: 10.1111/srt.13833.

References

Birdi G, Cooke R, Knibb R . Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020; 59(4):e75-e91. DOI: 10.1111/ijd.14763. View

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand J . Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017; 77(2):274-279.e3. DOI: 10.1016/j.jaad.2017.04.019. View

Abuabara K, Yu A, Okhovat J, Allen I, Langan S . The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2017; 73(3):696-704. PMC: 5830308. DOI: 10.1111/all.13320. View

Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T . Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013; 68(4):498-506. PMC: 7159470. DOI: 10.1111/all.12112. View

Bylund S, Kobyletzki L, Svalstedt M, Svensson A . Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020; 100(12):adv00160. PMC: 9189744. DOI: 10.2340/00015555-3510. View

Silverberg J, Kantor R . The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis. Dermatol Clin. 2017; 35(3):327-334. DOI: 10.1016/j.det.2017.02.005. View

Moyle M, Cevikbas F, Harden J, Guttman-Yassky E . Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol. 2019; 28(7):756-768. PMC: 6850480. DOI: 10.1111/exd.13911. View

Gandhi N, Pirozzi G, Graham N . Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017; 13(5):425-437. DOI: 10.1080/1744666X.2017.1298443. View

Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W . Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases. Adv Ther. 2017; 34(8):1989-2006. PMC: 5565673. DOI: 10.1007/s12325-017-0582-z. View

10.

de Bruin-Weller M, Gadkari A, Auziere S, Simpson E, Puig L, Barbarot S . The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2019; 34(5):1026-1036. PMC: 7318704. DOI: 10.1111/jdv.16003. View

11.

Macdonald L, Karow M, Stevens S, Auerbach W, Poueymirou W, Yasenchak J . Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014; 111(14):5147-52. PMC: 3986150. DOI: 10.1073/pnas.1323896111. View

12.

Murphy A, Macdonald L, Stevens S, Karow M, Dore A, Pobursky K . Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014; 111(14):5153-8. PMC: 3986188. DOI: 10.1073/pnas.1324022111. View

13.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather J, Weisman J, Pariser D . Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10086):2287-2303. DOI: 10.1016/S0140-6736(17)31191-1. View

14.

de Bruin-Weller M, Thaci D, Smith C, Reich K, Cork M, Radin A . Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III.... Br J Dermatol. 2017; 178(5):1083-1101. DOI: 10.1111/bjd.16156. View

15.

Simpson E, Bieber T, Guttman-Yassky E, Beck L, Blauvelt A, Cork M . Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016; 375(24):2335-2348. DOI: 10.1056/NEJMoa1610020. View

16.

de Bruin-Weller M, Pink A, Patrizi A, Gimenez-Arnau A, Agner T, Roquet-Gravy P . Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021; 32(2):164-173. DOI: 10.1080/09546634.2020.1866741. View

17.

Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M . The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001; 10(1):11-8. DOI: 10.1034/j.1600-0625.2001.100102.x. View

18.

Kunz B, Oranje A, Labreze L, Stalder J, Ring J, Taieb A . Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997; 195(1):10-9. DOI: 10.1159/000245677. View

19.

Charman C, Venn A, Williams H . The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004; 140(12):1513-9. DOI: 10.1001/archderm.140.12.1513. View

20.

Badia X, Mascaro J, Lozano R . Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999; 141(4):698-702. DOI: 10.1046/j.1365-2133.1999.03112.x. View